Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10640553B2 · kind B2 · utility
1Cited by
45References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 24, 2017 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | Jul 24, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/70
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.